$PALI
PALISADE BIO, INC.

2022 Q3 Form 10-Q Financial Statement

#000095017022017248 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.075M $2.255M $2.929M
YoY Change -13.25% -7.09% 70.29%
% of Gross Profit
Research & Development $1.928M $1.317M $959.0K
YoY Change 208.97% 319.43% 103.56%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $1.000K
YoY Change -100.0% -90.0%
% of Gross Profit
Operating Expenses $4.413M $3.572M $3.888M
YoY Change 46.32% -89.13% 98.98%
Operating Profit -$4.413M -$3.572M -$3.888M
YoY Change 46.32% -89.13% 98.98%
Interest Expense $4.000K $5.000K $1.000K
YoY Change -84.62% -99.24% -99.94%
% of Operating Profit
Other Income/Expense, Net $422.0K $1.228M -$317.0K
YoY Change -96.2% 10.43% -84.73%
Pretax Income -$3.991M -$2.344M -$4.205M
YoY Change -149.35% -92.62% 83.62%
Income Tax
% Of Pretax Income
Net Earnings -$3.991M -$2.344M -$4.205M
YoY Change -149.35% -92.62% 4.34%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08 -$0.12 -$12.96
Diluted Earnings Per Share -$0.08 -$0.12 -$259.2K
COMMON SHARES
Basic Shares Outstanding 21.88M 20.29M 18.23M
Diluted Shares Outstanding 48.71M 20.29M 324.5K

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.99M $4.980M $6.644M
YoY Change -0.84% -60.64% 1.28%
Cash & Equivalents $14.00M $5.000M $6.600M
Short-Term Investments
Other Short-Term Assets $1.153M $2.415M $1.528M
YoY Change -42.0% 19.97% -29.59%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $15.16M $7.415M $8.258M
YoY Change -5.8% -49.64% -5.68%
LONG-TERM ASSETS
Property, Plant & Equipment $12.00K $2.000K $2.000K
YoY Change 300.0% -33.33% -72.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $746.0K $26.00K $26.00K
YoY Change 2769.23% 0.0% 160.0%
Total Long-Term Assets $1.108M $391.0K $92.00K
YoY Change 508.79% 74.55% -42.26%
TOTAL ASSETS
Total Short-Term Assets $15.16M $7.415M $8.258M
Total Long-Term Assets $1.108M $391.0K $92.00K
Total Assets $16.27M $7.806M $8.350M
YoY Change -0.05% -47.78% -6.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.725M $1.041M $1.147M
YoY Change 24.73% -25.96% 120.58%
Accrued Expenses $1.242M $1.034M $580.0K
YoY Change 72.02% 8.27% 81.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $352.0K $611.0K $0.00
YoY Change -38.03% -46.45%
Total Short-Term Liabilities $3.513M $2.860M $1.864M
YoY Change 20.31% -25.71% 83.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $323.0K $735.0K $1.694M
YoY Change -96.58% -96.42% 896.47%
Total Long-Term Liabilities $323.0K $735.0K $1.694M
YoY Change 896.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.513M $2.860M $1.864M
Total Long-Term Liabilities $323.0K $735.0K $1.694M
Total Liabilities $3.836M $3.595M $3.558M
YoY Change -68.95% -85.26% 199.97%
SHAREHOLDERS EQUITY
Retained Earnings $105.2M $101.2M $98.80M
YoY Change -209.93% -197.5% -141.08%
Common Stock $771.0K $220.0K $183.0K
YoY Change 493.08% 92.98% 534.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.43M $4.211M $4.792M
YoY Change
Total Liabilities & Shareholders Equity $16.27M $7.806M $8.350M
YoY Change -0.05% -47.78% -6.34%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.991M -$2.344M -$4.205M
YoY Change -149.35% -92.62% 4.34%
Depreciation, Depletion And Amortization $0.00 $0.00 $1.000K
YoY Change -100.0% -90.0%
Cash From Operating Activities -$3.040M -$3.250M -$3.764M
YoY Change 10.71% -35.41% 201.12%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.05M 1.586M -87.00K
YoY Change 165.02% -92.31% -107.55%
NET CHANGE
Cash From Operating Activities -3.040M -3.250M -3.764M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 12.05M 1.586M -87.00K
Net Change In Cash 9.005M -1.664M -3.851M
YoY Change 520.61% -110.48% 3829.59%
FREE CASH FLOW
Cash From Operating Activities -$3.040M -$3.250M -$3.764M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Trading Symbol
TradingSymbol
PALI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Local Phone Number
LocalPhoneNumber
704-4900
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001357459
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33672
dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
dei Entity Address Address Line1
EntityAddressAddressLine1
7750 El Camino Real, Suite 5200
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92009
dei City Area Code
CityAreaCode
858
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21880169
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4980000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10495000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2435000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1879000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
7415000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
12374000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
363000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
109000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2022Q2 us-gaap Assets
Assets
7806000
CY2021Q4 us-gaap Assets
Assets
12512000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1041000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1323000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1034000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
463000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
76000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
511000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
98000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000
CY2022Q2 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
611000
CY2021Q4 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
87000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2860000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2496000
CY2022Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
469000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2651000
CY2022Q2 us-gaap Liabilities
Liabilities
3595000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
266000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Liabilities
Liabilities
5147000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21880169
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21880169
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14239177
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14239177
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
220000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105180000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101862000
CY2022Q2 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-101191000
CY2021Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-94642000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4211000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7806000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12512000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1317000
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
314000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2276000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1006000
CY2022Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2255000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2427000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5184000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3688000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3572000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
32858000
us-gaap Operating Expenses
OperatingExpenses
7460000
us-gaap Operating Expenses
OperatingExpenses
34811000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3572000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32858000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7460000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34811000
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
CY2022Q2 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
pali Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree
-135000
CY2021Q2 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1225000
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
5133000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2018000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
5175000
CY2022Q2 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
CY2021Q2 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
73000
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
73000
CY2022Q2 us-gaap Interest Expense
InterestExpense
5000
CY2021Q2 us-gaap Interest Expense
InterestExpense
655000
us-gaap Interest Expense
InterestExpense
6000
us-gaap Interest Expense
InterestExpense
2367000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000
CY2022Q2 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
CY2021Q2 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
CY2022Q2 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
CY2021Q2 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1574000
pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1110000
pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1574000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1228000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1112000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
911000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-965000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2344000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-31746000
us-gaap Net Income Loss
NetIncomeLoss
-6549000
us-gaap Net Income Loss
NetIncomeLoss
-35776000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.17
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.96
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20294652
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8831517
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18281788
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5803010
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20294652
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8984198
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
pali Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18281788
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5879351
pali Noncash Lease Expense
NoncashLeaseExpense
94000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2344000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31746000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6549000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35776000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2344000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-36865000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6549000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-40895000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4792000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2344000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
336000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4211000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-20063000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-31746000
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1184000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16000
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
28728000
CY2021Q2 pali Stock Acquired During Period Value
StockAcquiredDuringPeriodValue
2000
CY2021Q2 pali Adjustments To Additional Paid In Capital Restricted Stock Units Vested Upon Merger
AdjustmentsToAdditionalPaidInCapitalRestrictedStockUnitsVestedUponMerger
41000
CY2021Q2 pali Adjustments To Additional Paid In Capital Equity Warrant Put Rights Activated Upon Merger
AdjustmentsToAdditionalPaidInCapitalEquityWarrantPutRightsActivatedUponMerger
51000
CY2021Q2 pali Adjustments To Additional Paid In Capital Expiration Of Put Rights On Equity Classified Warrants
AdjustmentsToAdditionalPaidInCapitalExpirationOfPutRightsOnEquityClassifiedWarrants
26000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
495000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-9444000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
us-gaap Net Income Loss
NetIncomeLoss
-6549000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
694000
pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1274000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4211000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16602000
us-gaap Net Income Loss
NetIncomeLoss
-35776000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1184000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
28728000
pali Stock Acquired During Period Value
StockAcquiredDuringPeriodValue
2000
pali Adjustments To Additional Paid In Capital Restricted Stock Units Vested Upon Merger
AdjustmentsToAdditionalPaidInCapitalRestrictedStockUnitsVestedUponMerger
41000
pali Adjustments To Additional Paid In Capital Equity Warrant Put Rights Activated Upon Merger
AdjustmentsToAdditionalPaidInCapitalEquityWarrantPutRightsActivatedUponMerger
51000
pali Adjustments To Additional Paid In Capital Expiration Of Put Rights On Equity Classified Warrants
AdjustmentsToAdditionalPaidInCapitalExpirationOfPutRightsOnEquityClassifiedWarrants
26000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1064000
CY2021Q2 us-gaap Shares Outstanding
SharesOutstanding
0
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-9444000
us-gaap Net Income Loss
NetIncomeLoss
-6549000
us-gaap Net Income Loss
NetIncomeLoss
-35776000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
pali Noncash Lease Expense
NoncashLeaseExpense
80000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
16000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
us-gaap Accretion Expense
AccretionExpense
0
us-gaap Accretion Expense
AccretionExpense
2203000
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
1110000
pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
1574000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2018000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
5175000
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
73000
us-gaap Share Based Compensation
ShareBasedCompensation
694000
us-gaap Share Based Compensation
ShareBasedCompensation
1064000
pali Vesting Expense Restricted Stock Units
VestingExpenseRestrictedStockUnits
0
pali Vesting Expense Restricted Stock Units
VestingExpenseRestrictedStockUnits
41000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
213000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
183000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-25000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-228000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1294000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
170000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2133000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-435000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1518000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-96000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-79000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7014000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8972000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3279000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
2985000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
294000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
260000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
285000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1250000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
19900000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1775000
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
99000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
148000
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
80.72
CY2022Q2 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
9213008
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1499000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20618000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5515000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11940000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
739000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5006000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12679000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4980000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12653000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5006000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12679000
us-gaap Interest Paid Net
InterestPaidNet
5000
us-gaap Interest Paid Net
InterestPaidNet
50000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
355000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
pali Equity Issuance Costs Included In Accounts Payable And Accrued Liabilities
EquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
332000
pali Equity Issuance Costs Included In Accounts Payable And Accrued Liabilities
EquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
0
pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
1274000
pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
0
pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
55000
pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
0
pali Net Proceeds From Insurance Financing Arrangements Included In Prepaid And Other Assets
NetProceedsFromInsuranceFinancingArrangementsIncludedInPrepaidAndOtherAssets
784000
pali Net Proceeds From Insurance Financing Arrangements Included In Prepaid And Other Assets
NetProceedsFromInsuranceFinancingArrangementsIncludedInPrepaidAndOtherAssets
839000
pali Acquisitionrelated Costs Included In Accounts Payable And Accrued Liabilities
AcquisitionrelatedCostsIncludedInAccountsPayableAndAccruedLiabilities
0
pali Acquisitionrelated Costs Included In Accounts Payable And Accrued Liabilities
AcquisitionrelatedCostsIncludedInAccountsPayableAndAccruedLiabilities
367000
pali Noncash Transaction Costs Shared With Acquiree
NoncashTransactionCostsSharedWithAcquiree
0
pali Noncash Transaction Costs Shared With Acquiree
NoncashTransactionCostsSharedWithAcquiree
135000
pali Acquisition Costs Related To Stock Issuance
AcquisitionCostsRelatedToStockIssuance
0
pali Acquisition Costs Related To Stock Issuance
AcquisitionCostsRelatedToStockIssuance
1184000
pali Issuance Of Common Stock To Former Shareholders Of Acquiree
IssuanceOfCommonStockToFormerShareholdersOfAcquiree
0
pali Issuance Of Common Stock To Former Shareholders Of Acquiree
IssuanceOfCommonStockToFormerShareholdersOfAcquiree
28728000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
9503000
pali Assets Assumed1
AssetsAssumed1
0
pali Assets Assumed1
AssetsAssumed1
2000
pali Acquisition Related Vesting Of Rsus Assumed In Merger
AcquisitionRelatedVestingOfRsusAssumedInMerger
0
pali Acquisition Related Vesting Of Rsus Assumed In Merger
AcquisitionRelatedVestingOfRsusAssumedInMerger
41000
pali Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger
AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger
0
pali Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger
AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger
51000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
101200000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5000000.0
pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
2.74
pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y9M14D
CY2022Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2026-08-26
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">preparation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">assets </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to clinical trial accruals and the valuation of derivative liabilities and stock-based compensation instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q2 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
111250
CY2021Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
110000
CY2022Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
263000000
CY2021Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts.</span></p>
CY2022Q2 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
132000
CY2021Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
158000
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2344000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31746000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6549000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35776000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20294652
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8831517
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18281788
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5803010
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.17
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2344000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-31746000
us-gaap Net Income Loss
NetIncomeLoss
-6549000
us-gaap Net Income Loss
NetIncomeLoss
-35776000
CY2022Q2 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2021Q2 us-gaap Dilutive Securities
DilutiveSecurities
-5119000
us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
-5119000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2344000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-36865000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6549000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-40895000
CY2022Q2 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
20294652
CY2021Q2 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
8831517
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
18281788
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
5803010
CY2022Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2021Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
152681
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
76341
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20294652
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8984198
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18281788
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5879351
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.96
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11875942
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1668919
CY2022Q2 pali Accrued Accounts Payable
AccruedAccountsPayable
780000
CY2021Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
195000
CY2022Q2 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
132000
CY2021Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
158000
CY2022Q2 pali Accrued Director Stipends
AccruedDirectorStipends
111000
CY2021Q4 pali Accrued Director Stipends
AccruedDirectorStipends
110000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1034000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
463000
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
89922
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1818000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1408000
CY2022Q2 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
20000
CY2021Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
150000
CY2022Q2 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
212000
CY2021Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
215000
CY2022Q2 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
101000
CY2021Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
78000
CY2022Q2 pali Prepaid Expenses And Other Current Assets Deposits
PrepaidExpensesAndOtherCurrentAssetsDeposits
21000
CY2021Q4 pali Prepaid Expenses And Other Current Assets Deposits
PrepaidExpensesAndOtherCurrentAssetsDeposits
26000
CY2022Q2 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
263000
CY2021Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
0
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2435000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1879000
CY2021Q3 us-gaap Warrants And Rights Outstanding Measurement Input
WarrantsAndRightsOutstandingMeasurementInput
3900000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
9213008000
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7181741
CY2021Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
7181741
CY2021 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
5.96
CY2021 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y5M12D
pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
6115491
pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
0.85
pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P5Y2M26D
pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
3994302
pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
3.88
pali Class Of Warrant Or Right Exercised During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageRemainingContractualLife
P4Y1M9D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.89
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
17.72
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y9M21D
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0217
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0088
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7370
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7605
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1956855
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.32
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
699600
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.89
pali Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractualterm2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualterm2
P9Y8M8D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2656455
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M9D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2656455
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M9D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1145598
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M29D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.58
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
700000
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
377474
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.45
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
336000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
495000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
694000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1064000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M2D
CY2018 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000.0
CY2018 us-gaap Royalty Expense
RoyaltyExpense
6750000
CY2022Q2 pali Milestone Payments
MilestonePayments
0
pali Milestone Payments
MilestonePayments
0
CY2021Q2 pali Milestone Payments
MilestonePayments
0
pali Milestone Payments
MilestonePayments
0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
76000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
133000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
138000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
83000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
430000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
66000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
364000

Files In Submission

Name View Source Status
0000950170-22-017248-index-headers.html Edgar Link pending
0000950170-22-017248-index.html Edgar Link pending
0000950170-22-017248.txt Edgar Link pending
0000950170-22-017248-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img60046496_0.jpg Edgar Link pending
img60046496_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20220630.htm Edgar Link pending
pali-20220630.xsd Edgar Link pending
pali-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pali-20220630_cal.xml Edgar Link unprocessable
pali-ex10_2.htm Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pali-20220630_pre.xml Edgar Link unprocessable
pali-20220630_htm.xml Edgar Link completed
pali-20220630_lab.xml Edgar Link unprocessable